Skip directly to content

Referencias

1. Smolen JS, Breedveld FC, Burmester GR, et al. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis. 2016;75:3-15. doi:10.1136/annrheumdis-2015-207524.
2. Ramírez LA, Rodríguez C. Burden of illness of rheumatoid arthritis in Latin America: a regional perspective. Clin Rheumatol. 2015;34(suppl 19):S9-S15.
3. Henrique da Mota LM, Viegas Brenol C. Rheumatoid arthritis in Latin America: the importance of an early diagnosis. Clin Rheumatol. 2015;34(suppl 1):S29-S44.
4. Xavier RM, Morales-Torres J, Ramos-Remus DCR, et al. AB0306 Employment and quality of life among patients with rheumatoid arthritis in four Latin-American countries. Ann Rheum Dis. 2015;74:996.
5. De la Vega M, et al. Importance of a patient’s perspective in the management of rheumatoid arthritis in Argentina: sub-population analysis from a global patient-based survey. Poster presented at the XIX Pan-American League of Associations for Rheumatology Congress (PANLAR), Panama City, Panama, April 10–14, 2016.
6. Zerbini C, et al. Importance of a patient’s perspective in the management of rheumatoid arthritis in Brazil: sub-population analysis from a global patient-based survey. Poster presented at the XIX Pan-American League of Associations for Rheumatology Congress (PANLAR), Panama City, Panama, April 10–14, 2016.
7. Burgos R, Cardiel MH. Rheumatoid arthritis in Latin America. Important challenges to be solved. Clin Rheumatol. 2015;34(suppl 1):S1-S3.
8. Strand V, Kremer J, Wallenstein G, et al. Effects of tofacitinib monotherapy on patient-reported outcomes in a randomized phase 3 study of patients with active rheumatoid arthritis and inadequate responses to DMARDs. Arthritis Res & Ther. 2015;17:307-318.
9. Strand V, van Vollenhoven RF, Lee EB, et al. Tofacitinib or adalimumab versus placebo: patient-reported outcomes from a phase 3 study of active rheumatoid arthritis. Rheumatology (Oxford). 2016;55(6):1031-1041.
10. Strand V, Fleischmann R, Alten RE, et al. ORAL Start: Effects of the oral JAK inhibitor tofacitinib monotherapy versus methotrexate on patient-reported outcomes in the phase 3 ORAL Start trial of active rheumatoid arthritis. Ann Rheum Dis. 2013;72(suppl 3):252.


PP-XEL-COL-0315

Este material es de uso exclusivo para el cuerpo médico. ©Pfizer S.A.S. Todos los derechos reservados – Prohibida su reproducción total o parcial sin autorización del titular.

 Volver a menú